ANDREA KEANE: Open Payments
NPI 1720414915 · SEYMOUR, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$972 in 62 payments from 12 companies in 2025. Trend: 2023 $920 · 2024 $1,376 · 2025 $972
Food & beverage: $963Education: $9
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $172 |
| ABBVIE INC. | 12 | $172 |
| Indivior Inc. | 5 | $92 |
| Braeburn Inc. | 4 | $70 |
| Alkermes, Inc. | 3 | $68 |
| Lundbeck LLC | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Gilead Sciences, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
Products named: CAPLYTA, VRAYLAR, SUBLOCADE, REXULTI, ABILIFY MAINTENA, BRIXADI, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across IN — which companies pay providers there.
